• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Botha Roelof was granted 173 shares, increasing direct ownership by 3% to 6,690 units (SEC Form 4)

    7/29/25 9:05:09 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BOTHA ROELOF

    (Last) (First) (Middle)
    C/O NATERA, INC.
    13011 MCCALLEN PASS BUILDING A SUITE 100

    (Street)
    AUSTIN TX 78753

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Natera, Inc. [ NTRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/25/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/25/2025 A 173(1) A (2) 6,690 D
    Common Stock 1,224,787 I Estate planning vehicles
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $26,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.
    2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
    /s/ Vincent Fontanilla, Attorney-in-Fact 07/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NTRA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    12/29/2023$75.00 → $85.00Buy
    BTIG Research
    12/14/2023$70.00Buy
    Guggenheim
    12/13/2023$70.00Outperform
    Wolfe Research
    More analyst ratings

    $NTRA
    SEC Filings

    See more
    • SEC Form 144 filed by Natera Inc.

      144 - Natera, Inc. (0001604821) (Subject)

      7/29/25 4:25:28 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.

      SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)

      7/22/25 1:51:07 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Natera, Inc. (0001604821) (Filer)

      6/18/25 4:01:44 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO AND PRESIDENT Chapman Steven Leonard sold $851,712 worth of shares (6,092 units at $139.81), decreasing direct ownership by 3% to 169,400 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      7/30/25 9:45:09 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $700,670 worth of shares (5,064 units at $138.36), decreasing direct ownership by 7% to 65,430 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      7/30/25 9:45:05 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $240,191 worth of shares (1,718 units at $139.81), decreasing direct ownership by 0.07% to 2,360,852 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      7/30/25 9:35:11 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Natera Inc.

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      11/14/24 4:02:50 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Natera Inc. (Amendment)

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      6/7/24 12:07:25 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Natera Inc. (Amendment)

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      2/14/24 4:06:56 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Natera to Report Its Second Quarter Results on August 7, 2025

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information   Event:   Natera's Second Quarter 2025 Financial Results Date:   August 7, 2025 Time:   1:30 p.m. PT (4:30 p.m. ET) Live Dial-In:   1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID:   7684785 Webcast:  

      7/31/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

      Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive (HR+), HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera. Sponsored by the Austrian Breast & Colorectal Cancer Study G

      7/29/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

      First prospective, multi-center trial to examine how dd-cfDNA can be used in post-rejection patient management Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published findings from the PEDAL study. PEDAL is the first prospective multi-center trial evaluating longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine the prognostic ability of Prospera in assessing outcomes following kidney transplant rejection. PEDAL enrolled 488 kidney transplant recipients from 28 participating U.S. and international transplant centers over 4 years. 66 patients with biopsy-proven

      7/24/25 8:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on Natera with a new price target

      RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00

      3/13/25 8:17:14 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Natera with a new price target

      Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00

      1/23/25 7:51:22 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Jefferies resumed coverage on Natera with a new price target

      Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00

      6/3/24 8:16:05 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

      Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

      6/5/23 11:06:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

      Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

      2/23/23 8:05:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

      AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

      5/24/22 8:03:00 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Financials

    Live finance-specific insights

    See more
    • Natera to Report Its Second Quarter Results on August 7, 2025

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information   Event:   Natera's Second Quarter 2025 Financial Results Date:   August 7, 2025 Time:   1:30 p.m. PT (4:30 p.m. ET) Live Dial-In:   1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID:   7684785 Webcast:  

      7/31/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Reports First Quarter 2025 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

      5/8/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera to Report its First Quarter Results on May 8, 2025

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2025 Financial Results Date: May 8, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-596-4144 (Domestic) 1-646-968-2525 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/454317205 A webcast replay will be available at

      5/1/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care